Roche has confirmed that it will continue with its planned €600 million diagnostics production investment in Penzberg, Germany, even as other pharmaceutical companies reassess or reduce planned projects in the country.
The decision gives Germany a short-term vote of confidence. However, Roche also warned that future investments will be reviewed in light of policy changes and healthcare cost-cutting pressure.
That makes the message more cautious than celebratory.
For Germany, the challenge is balancing healthcare affordability with industrial competitiveness. For pharmaceutical companies, the issue is whether Europe can still provide stable conditions for long-cycle manufacturing and diagnostics investment.
Roche’s project may continue, but the broader investment climate is clearly under pressure.
